ArticlePloS one2026
Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the durability of effect and disease modification potential of a six-week course of pentosan polysulfate sodium (PPS) therapy out to 26 weeks (six months) in companion dogs with naturally-occurring osteoarthritis.
designTwenty mixed-breed companion dogs were enrolled and randomized to receive either subcutaneous 3 mg/kg PPS injections (n = 14) or placebo (n = 6) once weekly for six weeks. Dogs underwent assessments for pain, functional gait analysis, MRI, and biomarker analysis at baseline and selected timepoints.
resultsPPS treatment was well tolerated throughout the study. At baseline, the PPS-treated group had higher pain with Helsinki Chronic Pain Index (HCPI) scores of 15.14 compared to 8.83 in placebo. PPS-treated dogs experienced sustained HCPI reductions compared to placebo at 26 weeks after adjusting for differences in baseline pain. The PPS-treated group experienced normalization of gait symmetry up to week 26, indicating a reduction in lameness and an improvement in overall function. Total cartilage volume increased at weeks 8 and 26 from baseline in the PPS-treated group compared to placebo, and OA disease progression biomarker changes (CTX-I, HA, and TIMP-1) were consistent with slowed cartilage degradation at weeks 8 and 26.
conclusionsPPS-treated dogs experienced improvements in pain, joint function, and cartilage volume compared to placebo, supported by changes in biomarkers at weeks 8 and 26. The 26-week timepoint in this translational canine model provides insights into the potential disease-modifying mechanisms and durability of PPS in long-term treatment outcomes in humans with OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.